Quince Therapeutics financials
$31.17+7.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$81.1M | -$14.6M | -$19.4M | -$13.4M | -$10.4M | -$14.9M | -$12.0M | -$5.9M | -$28.2M | -$11.2M | -$9.9M | -$6.1M |
| Net income | -$75.5M | $32.8M | -$39.5M | -$13.4M | -$16.0M | -$15.0M | -$12.5M | -$5.5M | -$27.7M | -$11.1M | -$8.9M | -$5.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-12.31 | $57.60 | $-55.65 | $-50.00 | $-68.75 | $-68.40 | $-56.91 | $-26.00 | $-128.00 | $-52.00 | $-43.28 | $-30.00 |
| EBITDA | -$81.0M | -$11.1M | -$23.8M | -$11.3M | -$10.4M | -$12.9M | -$14.1M | -$8.5M | -$11.0M | -$8.6M | -$9.6M | -$6.1M |
| Operating cash flow | -$18.9M | -$7.6M | -$10.5M | -$9.9M | -$11.4M | -$9.6M | -$7.6M | -$7.3M | -$6.2M | -$10.9M | -$6.1M | -$4.8M |
| Free cash flow | -$18.9M | -$7.6M | -$10.5M | -$10.0M | -$11.5M | -$9.7M | -$7.7M | -$7.3M | -$6.2M | -$10.9M | -$6.1M | -$4.8M |
| Diluted shares | 6.1M | 0.5M | 0.7M | 0.3M | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M | 0.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $116.0M | $18.2M | $5.8M | $6.5M | $16.8M | $7.8M |
| Short-term investments | $0.00 | $0.00 | $11.9M | $19.8M | $17.9M | $23.8M |
| Total debt | $0.00 | $0.00 | $18.0M | $17.5M | $17.0M | $15.3M |
| Total assets | $124.0M | $26.6M | $93.5M | $109.9M | $117.2M | $107.1M |
| Total liabilities | $15.5M | $11.0M | $129.2M | $108.8M | $105.5M | $88.5M |
| Shareholders' equity | $108.5M | $15.7M | -$35.7M | $1.1M | $11.7M | $18.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology